CA 19-9 Kit ELISA

N° du produit ABIN930405

Détail du produit CA 19-9 Kit ELISA

Antigène: CA 19-9 (Gastrointestinal Cancer Antigen CA19-9 (CA 19-9))

Reactivité: Humain

Méthode de détection: Colorimetric

Type de méthode: Sandwich ELISA

Application: ELISA

Analytical Method: Quantitative

Attributs du produit: ELISA kit for the detection of CA 199 in the research laboratory
Alternative Names: CA 19-9 ELISA kit

Information d'application

Indications d'application: Optimal conditions to be determined by end user

Plaque: Pre-coated

Procédure de l'essai:

The CA 19-9 ELISA test is based on the principle of a solid phase enzymelinked immunosorbent assay. The assay system utilizes a monoclonal antibody directed against a distinct antigenic determinant on the intact CA 19-9 molecule is used for solid phase immobilization (on the microtiter wells). Another CA 19-9 monoclonal antibody conjugated to horseradish peroxidase (HRP) is in the antibodyenzyme conjugate solution. The test sample is allowed to react sequentially with the two antibodies, resulting in the CA 19-9 molecules being sandwiched between the solid phase and enzymelinked antibodies. After two separate incubation steps at 37 °C for 90 minutes, the wells are washed with water to remove unbound labeled antibodies. A solution of TMB Reagent is added and incubated for 20 minutes, resulting in the development of a blue color. The color development is stopped with the addition of Stop Solution ch anging the color to yellow. The concentration of CA 19-9 is directly proportional to the color intensity of the test sample. Absorbance is measured spectrophotometrically at 450 nm.

Restrictions: For Research Use only

Stockage

Stock: 4 °C

Stockage commentaire: Store at 2-8 °C.

Détail du antigène

Antigène: CA 19-9 (Gastrointestinal Cancer Antigen CA19-9 (CA 19-9))

Autre désignation: CA 19-9 (CA 19-9 Produits)

Classe de substances: Disease

Sujet: A group of mucin type glycoprotein Sialosyl Lewis Antigens (SLA), such as CA 19-9 and CA 19-5, have come to be recognized as circulating cancer associated antigens for gastrointestinal cancer. CA 19-9 represents the most important and basic carbohydrate tumor marker. The immunohistologic distribution of CA 19-9 in tissues is consistent with the quantitative determination of higher CA 19-9 concentrations in cancer than in normal or inflamed tissues. Recently reports indicates that the serum CA 19-9 level is frequently elevated in the serum of subjects with various gastrointestinal malignancies, such as pancreatic, colorectal, gastric and hepatic carcinomas. Together with CEA, elevated CA 19-9 is suggestive of gall-bladder neoplasm in the setting of inflammatory gallbladder disease. This tumor-associated antigen may also be elevated in some non-malignant conditions. Research studies demonstrate that serum CA 19-9 values may have utility in monitoring subjects with these diagnosed malignancies. It has been shown that a persistent elevation in serum CA 19-9 value following treatment may be indicative of occult metastatic and/or residual disease. A persistently rising serum CA 19-9 value may be associated with progressive malignant disease and poor therapeutic response. A declining CA 19-9 value may be indicative of a favorable prognosis and good response to treatment.
Synonyms: CA 19-9 ELISA kit.